Clinical Outcome and Reversibility of Systolic Dysfunction in Patients With Dilated Cardiomyopathy Due to Hypertension and Chronic Heart Failure
There is little information on the clinical and functional course of patients with heart failure secondary to dilated cardiomyopathy due to hypertension. The objectives of our study were to assess the clinical and functional course of these patients, and to identify possible predictors of prognosis....
Gespeichert in:
| Veröffentlicht in: | Revista española de cardiologia 2004-09, Vol.57 (9), p.834-841 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng ; spa |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 841 |
|---|---|
| container_issue | 9 |
| container_start_page | 834 |
| container_title | Revista española de cardiologia |
| container_volume | 57 |
| creator | Anguita Sánchez, Manuel Rodríguez Esteban, Marcos Ojeda Pineda, Soledad Ruiz Ortiz, Martín Romo Peña, Elías Mesa Rubio, Dolores Vallés Belsué, Federico |
| description | There is little information on the clinical and functional course of patients with heart failure secondary to dilated cardiomyopathy due to hypertension. The objectives of our study were to assess the clinical and functional course of these patients, and to identify possible predictors of prognosis.
We evaluated a series of 49 patients with this condition diagnosed in our hospital from 1994 to 2003. Mean age was 63 (11) years, and 40% were women. Left ventricular ejection fraction was 30.1 (4.8)%. Follow-up was 45 (23) months (median, 41 months).
Four-year survival was 0.84, the 4-year rate of hospitalization due to heart failure was 0.12, and likelihood of readmission-free survival was 0.80 at 4 years. Left ventricular ejection fraction increased from 30.1 (4.8)% to 57.6 (13.5)% (
P |
| doi_str_mv | 10.1016/S1885-5857(06)60648-8 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_66893691</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1885585706606488</els_id><sourcerecordid>66893691</sourcerecordid><originalsourceid>FETCH-LOGICAL-c293t-cc49281ed57f1b74bd492852e2c42dce1dd7ba73149c9004986a3a1c381810cc3</originalsourceid><addsrcrecordid>eNqFUctu1DAUtRCIPuATQF4hugjYceLYK4QybQepUhEFsbQc-0Zj5MSD7VTKX_DJTTojYNfVfeice3TPQegNJR8oofzjHRWiLmpRN-8Jv-CEV6IQz9Dp3_Xz__oTdJbSL0JqJprqJTqhNWuYFPIU_Wm9G53RHt9O2YQBsB4t_gb3EJPrnHd5xqHHd3PKwTuDN3Pqp9FkF0bsRvxVZwdjTvinyzu8cV5nsLjV0bowzGGv827GmwlwDng77yFmGNPKXVXaXQyLNt6CjhlfaeenCK_Qi177BK-P9Rz9uLr83m6Lm9vrL-3nm8KUkuXCmEqWgoKtm552TdXZda5LKE1VWgPU2qbTDaOVNJKQSgqumaaGCSooMYado3eHu_sYfk-QshpcMuC9HiFMSXEuJOOSLsD6ADQxpBShV_voBh1nRYlao1CPUajVZ0W4eoxCiYX39igwdQPYf6yj9wvg0wEAy5v3DqJKZjHTgHURTFY2uCckHgBRGJup</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>66893691</pqid></control><display><type>article</type><title>Clinical Outcome and Reversibility of Systolic Dysfunction in Patients With Dilated Cardiomyopathy Due to Hypertension and Chronic Heart Failure</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><creator>Anguita Sánchez, Manuel ; Rodríguez Esteban, Marcos ; Ojeda Pineda, Soledad ; Ruiz Ortiz, Martín ; Romo Peña, Elías ; Mesa Rubio, Dolores ; Vallés Belsué, Federico</creator><creatorcontrib>Anguita Sánchez, Manuel ; Rodríguez Esteban, Marcos ; Ojeda Pineda, Soledad ; Ruiz Ortiz, Martín ; Romo Peña, Elías ; Mesa Rubio, Dolores ; Vallés Belsué, Federico</creatorcontrib><description>There is little information on the clinical and functional course of patients with heart failure secondary to dilated cardiomyopathy due to hypertension. The objectives of our study were to assess the clinical and functional course of these patients, and to identify possible predictors of prognosis.
We evaluated a series of 49 patients with this condition diagnosed in our hospital from 1994 to 2003. Mean age was 63 (11) years, and 40% were women. Left ventricular ejection fraction was 30.1 (4.8)%. Follow-up was 45 (23) months (median, 41 months).
Four-year survival was 0.84, the 4-year rate of hospitalization due to heart failure was 0.12, and likelihood of readmission-free survival was 0.80 at 4 years. Left ventricular ejection fraction increased from 30.1 (4.8)% to 57.6 (13.5)% (
P<.001). An unfavorable clinical and functional outcome at 4 years (death, readmission for heart failure or persistence of dilated cardiomyopathy) was recorded in only in 40% of the patients. Multivariate analysis with the Cox model showed appropriate control of blood pressure to be the only independent predictor of a favorable clinical outcome (absence of death or readmission for heart failure) (hazard ratio = 4.58; 95% CI, 1.32-9.83;
P=.032).
The course of patients with severe dilated cardiomyopathy due to hypertension was favorable in 60% of cases. Adequate control of blood pressure was the only independent predictor of a favorable clinical outcome.
Hay poca información sobre la evolución clínica y funcional de los pacientes con insuficiencia cardíaca secundaria a miocardiopatía dilatada de origen hipertensivo. Los objetivos de nuestro trabajo son estudiar la evolución clínica y funcional de estos pacientes, así como identificar los posibles factores predictores de esta evolución.
Para ello, hemos evaluado a una serie de 57 pacientes diagnosticados en nuestro centro entre 1994 y 2003 con dicho problema. La edad media de los pacientes fue de 63 ± 11 años, y el 40% eran mujeres. La fracción de eyección ventricular izquierda era del 30,1 ± 4,8%. El tiempo de seguimiento fue de 45 ± 23 meses (mediana, 41 meses).
La supervivencia a los 4 años fue 0,84, la tasa de reingresos por insuficiencia cardíaca, 0,12 y la supervivencia libre de reingresos, 0,80. La fracción de eyección aumentó desde el 30,1 ± 4,8% hasta el 57,6 ± 13,5% (
p < 0,001). En conjunto, sólo el 40% de los pacientes presentó mala evolución clínica y/o funcional (muerte, reingreso por insuficiencia cardíaca, persistencia de miocardiopatía dilatada) al final del seguimiento. En el estudio multivariable (modelo de Cox), el adecuado control de la presión arterial fue el único predictor independiente de buena evolución clínica (ausencia de muerte y/o reingreso por insuficiencia cardíaca; razón de riesgo = 4,58; intervalo de confianza del 95%, 1,32-9,83;
p = 0,032).
La evolución de los pacientes con miocardiopatía dilatada hipertensiva severa es buena en el 60% de los casos. El control de la presión arterial fue el único predictor independiente de buena evolución clínica.</description><identifier>ISSN: 1885-5857</identifier><identifier>ISSN: 0300-8932</identifier><identifier>EISSN: 1885-5857</identifier><identifier>DOI: 10.1016/S1885-5857(06)60648-8</identifier><identifier>PMID: 15373989</identifier><language>eng ; spa</language><publisher>Spain: Elsevier Espana</publisher><subject>Cardiomyopathy, Dilated - complications ; Cardiomyopathy, Dilated - drug therapy ; Cardiomyopathy, Dilated - mortality ; Cardiovascular Agents - therapeutic use ; Dilated cardiomyopathy ; Female ; Heart failure ; Heart Failure - complications ; Heart Failure - drug therapy ; Heart Failure - mortality ; Hipertensión arterial ; Humans ; Hypertension - complications ; Hypertension - drug therapy ; Hypertension - mortality ; Insuficiencia cardíaca ; Male ; Middle Aged ; Miocardiopatía dilatada ; Multivariate Analysis ; Prognosis ; Recovery of Function ; Survival Analysis ; Systemic hypertension ; Systole ; Treatment Outcome ; Ventricular Dysfunction, Left - complications ; Ventricular Dysfunction, Left - drug therapy ; Ventricular Dysfunction, Left - mortality</subject><ispartof>Revista española de cardiologia, 2004-09, Vol.57 (9), p.834-841</ispartof><rights>2004 Sociedad Española de Cardiología</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c293t-cc49281ed57f1b74bd492852e2c42dce1dd7ba73149c9004986a3a1c381810cc3</citedby><cites>FETCH-LOGICAL-c293t-cc49281ed57f1b74bd492852e2c42dce1dd7ba73149c9004986a3a1c381810cc3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S1885585706606488$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15373989$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Anguita Sánchez, Manuel</creatorcontrib><creatorcontrib>Rodríguez Esteban, Marcos</creatorcontrib><creatorcontrib>Ojeda Pineda, Soledad</creatorcontrib><creatorcontrib>Ruiz Ortiz, Martín</creatorcontrib><creatorcontrib>Romo Peña, Elías</creatorcontrib><creatorcontrib>Mesa Rubio, Dolores</creatorcontrib><creatorcontrib>Vallés Belsué, Federico</creatorcontrib><title>Clinical Outcome and Reversibility of Systolic Dysfunction in Patients With Dilated Cardiomyopathy Due to Hypertension and Chronic Heart Failure</title><title>Revista española de cardiologia</title><addtitle>Rev Esp Cardiol</addtitle><description>There is little information on the clinical and functional course of patients with heart failure secondary to dilated cardiomyopathy due to hypertension. The objectives of our study were to assess the clinical and functional course of these patients, and to identify possible predictors of prognosis.
We evaluated a series of 49 patients with this condition diagnosed in our hospital from 1994 to 2003. Mean age was 63 (11) years, and 40% were women. Left ventricular ejection fraction was 30.1 (4.8)%. Follow-up was 45 (23) months (median, 41 months).
Four-year survival was 0.84, the 4-year rate of hospitalization due to heart failure was 0.12, and likelihood of readmission-free survival was 0.80 at 4 years. Left ventricular ejection fraction increased from 30.1 (4.8)% to 57.6 (13.5)% (
P<.001). An unfavorable clinical and functional outcome at 4 years (death, readmission for heart failure or persistence of dilated cardiomyopathy) was recorded in only in 40% of the patients. Multivariate analysis with the Cox model showed appropriate control of blood pressure to be the only independent predictor of a favorable clinical outcome (absence of death or readmission for heart failure) (hazard ratio = 4.58; 95% CI, 1.32-9.83;
P=.032).
The course of patients with severe dilated cardiomyopathy due to hypertension was favorable in 60% of cases. Adequate control of blood pressure was the only independent predictor of a favorable clinical outcome.
Hay poca información sobre la evolución clínica y funcional de los pacientes con insuficiencia cardíaca secundaria a miocardiopatía dilatada de origen hipertensivo. Los objetivos de nuestro trabajo son estudiar la evolución clínica y funcional de estos pacientes, así como identificar los posibles factores predictores de esta evolución.
Para ello, hemos evaluado a una serie de 57 pacientes diagnosticados en nuestro centro entre 1994 y 2003 con dicho problema. La edad media de los pacientes fue de 63 ± 11 años, y el 40% eran mujeres. La fracción de eyección ventricular izquierda era del 30,1 ± 4,8%. El tiempo de seguimiento fue de 45 ± 23 meses (mediana, 41 meses).
La supervivencia a los 4 años fue 0,84, la tasa de reingresos por insuficiencia cardíaca, 0,12 y la supervivencia libre de reingresos, 0,80. La fracción de eyección aumentó desde el 30,1 ± 4,8% hasta el 57,6 ± 13,5% (
p < 0,001). En conjunto, sólo el 40% de los pacientes presentó mala evolución clínica y/o funcional (muerte, reingreso por insuficiencia cardíaca, persistencia de miocardiopatía dilatada) al final del seguimiento. En el estudio multivariable (modelo de Cox), el adecuado control de la presión arterial fue el único predictor independiente de buena evolución clínica (ausencia de muerte y/o reingreso por insuficiencia cardíaca; razón de riesgo = 4,58; intervalo de confianza del 95%, 1,32-9,83;
p = 0,032).
La evolución de los pacientes con miocardiopatía dilatada hipertensiva severa es buena en el 60% de los casos. El control de la presión arterial fue el único predictor independiente de buena evolución clínica.</description><subject>Cardiomyopathy, Dilated - complications</subject><subject>Cardiomyopathy, Dilated - drug therapy</subject><subject>Cardiomyopathy, Dilated - mortality</subject><subject>Cardiovascular Agents - therapeutic use</subject><subject>Dilated cardiomyopathy</subject><subject>Female</subject><subject>Heart failure</subject><subject>Heart Failure - complications</subject><subject>Heart Failure - drug therapy</subject><subject>Heart Failure - mortality</subject><subject>Hipertensión arterial</subject><subject>Humans</subject><subject>Hypertension - complications</subject><subject>Hypertension - drug therapy</subject><subject>Hypertension - mortality</subject><subject>Insuficiencia cardíaca</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Miocardiopatía dilatada</subject><subject>Multivariate Analysis</subject><subject>Prognosis</subject><subject>Recovery of Function</subject><subject>Survival Analysis</subject><subject>Systemic hypertension</subject><subject>Systole</subject><subject>Treatment Outcome</subject><subject>Ventricular Dysfunction, Left - complications</subject><subject>Ventricular Dysfunction, Left - drug therapy</subject><subject>Ventricular Dysfunction, Left - mortality</subject><issn>1885-5857</issn><issn>0300-8932</issn><issn>1885-5857</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2004</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFUctu1DAUtRCIPuATQF4hugjYceLYK4QybQepUhEFsbQc-0Zj5MSD7VTKX_DJTTojYNfVfeice3TPQegNJR8oofzjHRWiLmpRN-8Jv-CEV6IQz9Dp3_Xz__oTdJbSL0JqJprqJTqhNWuYFPIU_Wm9G53RHt9O2YQBsB4t_gb3EJPrnHd5xqHHd3PKwTuDN3Pqp9FkF0bsRvxVZwdjTvinyzu8cV5nsLjV0bowzGGv827GmwlwDng77yFmGNPKXVXaXQyLNt6CjhlfaeenCK_Qi177BK-P9Rz9uLr83m6Lm9vrL-3nm8KUkuXCmEqWgoKtm552TdXZda5LKE1VWgPU2qbTDaOVNJKQSgqumaaGCSooMYado3eHu_sYfk-QshpcMuC9HiFMSXEuJOOSLsD6ADQxpBShV_voBh1nRYlao1CPUajVZ0W4eoxCiYX39igwdQPYf6yj9wvg0wEAy5v3DqJKZjHTgHURTFY2uCckHgBRGJup</recordid><startdate>20040901</startdate><enddate>20040901</enddate><creator>Anguita Sánchez, Manuel</creator><creator>Rodríguez Esteban, Marcos</creator><creator>Ojeda Pineda, Soledad</creator><creator>Ruiz Ortiz, Martín</creator><creator>Romo Peña, Elías</creator><creator>Mesa Rubio, Dolores</creator><creator>Vallés Belsué, Federico</creator><general>Elsevier Espana</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20040901</creationdate><title>Clinical Outcome and Reversibility of Systolic Dysfunction in Patients With Dilated Cardiomyopathy Due to Hypertension and Chronic Heart Failure</title><author>Anguita Sánchez, Manuel ; Rodríguez Esteban, Marcos ; Ojeda Pineda, Soledad ; Ruiz Ortiz, Martín ; Romo Peña, Elías ; Mesa Rubio, Dolores ; Vallés Belsué, Federico</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c293t-cc49281ed57f1b74bd492852e2c42dce1dd7ba73149c9004986a3a1c381810cc3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng ; spa</language><creationdate>2004</creationdate><topic>Cardiomyopathy, Dilated - complications</topic><topic>Cardiomyopathy, Dilated - drug therapy</topic><topic>Cardiomyopathy, Dilated - mortality</topic><topic>Cardiovascular Agents - therapeutic use</topic><topic>Dilated cardiomyopathy</topic><topic>Female</topic><topic>Heart failure</topic><topic>Heart Failure - complications</topic><topic>Heart Failure - drug therapy</topic><topic>Heart Failure - mortality</topic><topic>Hipertensión arterial</topic><topic>Humans</topic><topic>Hypertension - complications</topic><topic>Hypertension - drug therapy</topic><topic>Hypertension - mortality</topic><topic>Insuficiencia cardíaca</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Miocardiopatía dilatada</topic><topic>Multivariate Analysis</topic><topic>Prognosis</topic><topic>Recovery of Function</topic><topic>Survival Analysis</topic><topic>Systemic hypertension</topic><topic>Systole</topic><topic>Treatment Outcome</topic><topic>Ventricular Dysfunction, Left - complications</topic><topic>Ventricular Dysfunction, Left - drug therapy</topic><topic>Ventricular Dysfunction, Left - mortality</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Anguita Sánchez, Manuel</creatorcontrib><creatorcontrib>Rodríguez Esteban, Marcos</creatorcontrib><creatorcontrib>Ojeda Pineda, Soledad</creatorcontrib><creatorcontrib>Ruiz Ortiz, Martín</creatorcontrib><creatorcontrib>Romo Peña, Elías</creatorcontrib><creatorcontrib>Mesa Rubio, Dolores</creatorcontrib><creatorcontrib>Vallés Belsué, Federico</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Revista española de cardiologia</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Anguita Sánchez, Manuel</au><au>Rodríguez Esteban, Marcos</au><au>Ojeda Pineda, Soledad</au><au>Ruiz Ortiz, Martín</au><au>Romo Peña, Elías</au><au>Mesa Rubio, Dolores</au><au>Vallés Belsué, Federico</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Clinical Outcome and Reversibility of Systolic Dysfunction in Patients With Dilated Cardiomyopathy Due to Hypertension and Chronic Heart Failure</atitle><jtitle>Revista española de cardiologia</jtitle><addtitle>Rev Esp Cardiol</addtitle><date>2004-09-01</date><risdate>2004</risdate><volume>57</volume><issue>9</issue><spage>834</spage><epage>841</epage><pages>834-841</pages><issn>1885-5857</issn><issn>0300-8932</issn><eissn>1885-5857</eissn><abstract>There is little information on the clinical and functional course of patients with heart failure secondary to dilated cardiomyopathy due to hypertension. The objectives of our study were to assess the clinical and functional course of these patients, and to identify possible predictors of prognosis.
We evaluated a series of 49 patients with this condition diagnosed in our hospital from 1994 to 2003. Mean age was 63 (11) years, and 40% were women. Left ventricular ejection fraction was 30.1 (4.8)%. Follow-up was 45 (23) months (median, 41 months).
Four-year survival was 0.84, the 4-year rate of hospitalization due to heart failure was 0.12, and likelihood of readmission-free survival was 0.80 at 4 years. Left ventricular ejection fraction increased from 30.1 (4.8)% to 57.6 (13.5)% (
P<.001). An unfavorable clinical and functional outcome at 4 years (death, readmission for heart failure or persistence of dilated cardiomyopathy) was recorded in only in 40% of the patients. Multivariate analysis with the Cox model showed appropriate control of blood pressure to be the only independent predictor of a favorable clinical outcome (absence of death or readmission for heart failure) (hazard ratio = 4.58; 95% CI, 1.32-9.83;
P=.032).
The course of patients with severe dilated cardiomyopathy due to hypertension was favorable in 60% of cases. Adequate control of blood pressure was the only independent predictor of a favorable clinical outcome.
Hay poca información sobre la evolución clínica y funcional de los pacientes con insuficiencia cardíaca secundaria a miocardiopatía dilatada de origen hipertensivo. Los objetivos de nuestro trabajo son estudiar la evolución clínica y funcional de estos pacientes, así como identificar los posibles factores predictores de esta evolución.
Para ello, hemos evaluado a una serie de 57 pacientes diagnosticados en nuestro centro entre 1994 y 2003 con dicho problema. La edad media de los pacientes fue de 63 ± 11 años, y el 40% eran mujeres. La fracción de eyección ventricular izquierda era del 30,1 ± 4,8%. El tiempo de seguimiento fue de 45 ± 23 meses (mediana, 41 meses).
La supervivencia a los 4 años fue 0,84, la tasa de reingresos por insuficiencia cardíaca, 0,12 y la supervivencia libre de reingresos, 0,80. La fracción de eyección aumentó desde el 30,1 ± 4,8% hasta el 57,6 ± 13,5% (
p < 0,001). En conjunto, sólo el 40% de los pacientes presentó mala evolución clínica y/o funcional (muerte, reingreso por insuficiencia cardíaca, persistencia de miocardiopatía dilatada) al final del seguimiento. En el estudio multivariable (modelo de Cox), el adecuado control de la presión arterial fue el único predictor independiente de buena evolución clínica (ausencia de muerte y/o reingreso por insuficiencia cardíaca; razón de riesgo = 4,58; intervalo de confianza del 95%, 1,32-9,83;
p = 0,032).
La evolución de los pacientes con miocardiopatía dilatada hipertensiva severa es buena en el 60% de los casos. El control de la presión arterial fue el único predictor independiente de buena evolución clínica.</abstract><cop>Spain</cop><pub>Elsevier Espana</pub><pmid>15373989</pmid><doi>10.1016/S1885-5857(06)60648-8</doi><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1885-5857 |
| ispartof | Revista española de cardiologia, 2004-09, Vol.57 (9), p.834-841 |
| issn | 1885-5857 0300-8932 1885-5857 |
| language | eng ; spa |
| recordid | cdi_proquest_miscellaneous_66893691 |
| source | MEDLINE; Elsevier ScienceDirect Journals Complete; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals |
| subjects | Cardiomyopathy, Dilated - complications Cardiomyopathy, Dilated - drug therapy Cardiomyopathy, Dilated - mortality Cardiovascular Agents - therapeutic use Dilated cardiomyopathy Female Heart failure Heart Failure - complications Heart Failure - drug therapy Heart Failure - mortality Hipertensión arterial Humans Hypertension - complications Hypertension - drug therapy Hypertension - mortality Insuficiencia cardíaca Male Middle Aged Miocardiopatía dilatada Multivariate Analysis Prognosis Recovery of Function Survival Analysis Systemic hypertension Systole Treatment Outcome Ventricular Dysfunction, Left - complications Ventricular Dysfunction, Left - drug therapy Ventricular Dysfunction, Left - mortality |
| title | Clinical Outcome and Reversibility of Systolic Dysfunction in Patients With Dilated Cardiomyopathy Due to Hypertension and Chronic Heart Failure |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-12T18%3A40%3A06IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Clinical%20Outcome%20and%20Reversibility%20of%20Systolic%20Dysfunction%20in%20Patients%20With%20Dilated%20Cardiomyopathy%20Due%20to%20Hypertension%20and%20Chronic%20Heart%20Failure&rft.jtitle=Revista%20espa%C3%B1ola%20de%20cardiologia&rft.au=Anguita%20S%C3%A1nchez,%20Manuel&rft.date=2004-09-01&rft.volume=57&rft.issue=9&rft.spage=834&rft.epage=841&rft.pages=834-841&rft.issn=1885-5857&rft.eissn=1885-5857&rft_id=info:doi/10.1016/S1885-5857(06)60648-8&rft_dat=%3Cproquest_cross%3E66893691%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=66893691&rft_id=info:pmid/15373989&rft_els_id=S1885585706606488&rfr_iscdi=true |